Aptadir Therapeutics

Aptadir Therapeutics

HealthRNA TherapeuticsB2B📍 Italy

Aptadir Therapeutics is developing a new class of RNA inhibitor-based therapeutics called DNMTs Interacting RNAs (DiRs) to address genetic disorders and oncology. Their platform aims to reactivate silenced genes and restore normal biological functions, potentially offering a way to treat previously irreversible genetic diseases. This seed round will advance their lead candidate for Fragile X Syndrome towards clinical development.

Total raised
Undisclosed
across 2 rounds
Latest round
Seed
Oct 2, 2026
Known investors
1
led by CE-Ventures
Press coverage
2
outlets tracked

Is this your company?

Claim this profile to get matched with investors who fund Health startups in Italy.

Claim this profile →

Funding history

  1. 2
    €40 millionSeedOct 2, 2026

    Led by CE-Ventures

    Announcement ↗
  2. 1
    USD 45.4MSeedSep 30, 2026
    Announcement ↗

Founder

Giovanni Amabile
Giovanni Amabile
CEO and Founder

Investors in Aptadir Therapeutics

Backers from this company's tracked funding rounds.

  • CCE-VenturesLead investorVC firm

Aptadir Therapeutics in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile